Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Bone biomarkers are going to be incorporated into the phase III trials of the combination of docetaxel and radium-223 dichloride (Xofigo), explains Morris. At this point the biomarkers do not impact clinical management, but research is being conducted to find biomarkers that can be prospectively followed by the clinicians and used to determine whether a patient is favorably responding to a treatment or not.

According to Morris, it is important to look at this in terms of prostate-specific antigen (PSA) versus bone biomarkers because with the combination, it is not known which will be most significantly impacted.